Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderly EXPERIMENTAL GERONTOLOGY Diaz-Borjon, A., Weyand, C. M., Goronzy, J. J. 2006; 41 (12): 1250-1255

Abstract

The treatment armamentarium in rheumatic inflammatory diseases has drastically increased in the last years. Earlier uses of conventional disease-modifying antirheumatic drugs (DMARDs), along with the arrival of newer therapies including the so-called "biologic" agents, have provided better long-term outcomes for patients suffering from these illnesses. Biologic agents have shown efficacy for several diseases and failed in others. Due to a high prevalence of some of these diseases in the elderly population, this age group may also benefit, although treatment will have to be tailored to its special needs. In this mini review, we will discuss the use of these medications in rheumatic diseases with a significant prevalence in the elderly, their proven and potential uses, and the considerations that need to be taken into account when using them in this population.

View details for DOI 10.1016/j.exger.2006.10.010

View details for Web of Science ID 000243219800012

View details for PubMedID 17125948